Specifically, high PPARγ mRNA expression was found to be significantly correlated with longer median overall survival (OS) (HR = 0.69 (0.57–0.84), p = 0.00022), recurrence free survival (RSF) (HR = 0.82 (0.74–0.91), p = 0.00014), post-progression survival (PPS) (HR = 0.79 (0.63–1), p = 0.05), and distant metastasis free survival (DMFS) (HR = 0.78 (0.67–0.91), p = 0.0017) for all breast cancer patients. Here, PPARG is linked to breast cancer.